Liu Xuejie

Ms. Liu Xuejie

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2024 in Viruses
Verified
Journal Article
Open access
PDF file
茜谢茜 谢
茜 谢
LWLiangliang Wang
Liangliang Wang
XLXinzhong Liao
Xinzhong Liao
BHBi Huang
Bi Huang
CLChuming Luo
Chuming Luo
YSYuelong Shu
Yuelong Shu
Interferon-induced transmembrane proteins (IFITMs) are upregulated by interferons. They are not only highly conserved in evolution but also structurally consistent and have almost identical structural domains and functional domains. They are all transmembrane proteins and have multiple heritable variations in genes. The IFITM protein family is closely related to a variety of biological functions, including antiviral immunity, tumor formation, bone metabolism, cell adhesion, differentiation, and intracellular signal transduction. The progress of the research on its structure and related functions, as represented by IFITM3, is reviewed.

6 August 2024 in EBioMedicine
Verified
Journal Article
Open access
LYLifang Yuan
Lifang Yuan
SZShengze Zhang
Shengze Zhang
RBRongjun Bi
Rongjun Bi
LXLiu Xuejie
Liu Xuejie
ZHZirong Han
Zirong Han
YSYuelong Shu
Yuelong Shu
Influenza viruses pose a persistent threat to global public health, necessitating the development of innovative and broadly effective vaccines. This study focuses on a multiepitope vaccine (MEV) designed to provide broad-spectrum protection against different influenza viruses. The MEV, containing 19 B-cell linear epitopes, 7 CD4+ T cells, and 11 CD8+ T cells epitopes identified through enzyme-linked immunospot assay (ELISPOT) in influenza viruses infected mice, was administered through a regimen of two doses of DNA vaccine followed by one dose of a protein vaccine in C57BL/6 female mice. Upon lethal challenge with both seasonal circulating strains (H1N1, H3N2, BV, and BY) and historical strains (H1N1-PR8 and H3N2-X31), MEV demonstrated substantial protection against different influenza seasonal strains, with partial efficacy against historical strains. Notably, the increased germinal centre B cells and antibody-secreting cells, along with robust T cell immune responses, highlighted the comprehensive immune defence elicited by MEV. Elevated hemagglutinin inhibition antibody was also observed against seasonal circulating and historical strains. Additionally, mice vaccinated with MEV exhibited significantly lower counts of inflammatory cells in the lungs compared to negative control groups. Our results demonstrated the efficacy of a broad-spectrum MEV against influenza viruses in mice. Conducting long-term studies to evaluate the durability of MEV-induced immune responses and explore its potential application in diverse populations will offer valuable insights for the continued advancement of this promising vaccine. Funding bodies are described in the Acknowledgments section.

7 January 2020 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
LXLiu Xuejie
Liu Xuejie
JZJingHua Zhao
JingHua Zhao
LZLiangYu Zhang
LiangYu Zhang
JLJing Lu
Jing Lu
XLXiaoPing Lv
XiaoPing Lv
XGXueLi Gao
XueLi Gao

2 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
LXLiu Xuejie
Liu Xuejie
CLChuming Luo
Chuming Luo
ZYZhuolin Yang
Zhuolin Yang
TZTianyi Zhao
Tianyi Zhao
LYLifang Yuan
Lifang Yuan
YSYuelong Shu
Yuelong Shu
The annual co-circulation of two influenza A subtypes, H1N1 and H3N2, viruses in humans poses significant public health threats worldwide. However, the continuous antigenic drift and shift of influenza viruses limited the effectiveness of current seasonal influenza vaccines, necessitating the development of new vaccines against both seasonal and pandemic viruses. One potential solution to this challenge is to improve inactivated vaccines by including multiple T-cell epitopes. In this study, we designed stabilized trimeric recombinant mosaic HA proteins named HAm, which contain the most potential HA T-cell epitopes of seasonal influenza A virus. We further evaluated the antigenicity, hemagglutinin activity, and structural integrity of HAm and compared its immunogenicity and efficacy to a commercial quadrivalent inactivated influenza vaccine (QIV) in mice. Our results demonstrated that the HAm vaccine was able to induce broadly cross-reactive antibodies and T-cell responses against homologous, heterologous, and heterosubtypic influenza-naive mice. Additionally, the HAm antigens outperformed QIV vaccine antigens by eliciting protective antibodies against panels of antigenically drifted influenza vaccine strains from 2009 to 2024 and protecting against ancestral viruses’ lethal challenge. These results suggest that the HAm vaccine is a promising potential candidate for future universal seasonal and pandemic influenza vaccine development.